Agueda Rostagno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5658389/publications.pdf

Version: 2024-02-01

49 papers	3,029 citations	186265 28 h-index	233421 45 g-index
60 all docs	60 docs citations	60 times ranked	3620 citing authors

#	Article	IF	Citations
1	A stop-codon mutation in the BRI gene associated with familial British dementia. Nature, 1999, 399, 776-781.	27.8	467
2	Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica, 2009, 118, 115-130.	7.7	255
3	Cerebral Amyloid Angiopathies: A Pathologic, Biochemical, and Genetic View. Journal of Neuropathology and Experimental Neurology, 2003, 62, 885-898.	1.7	245
4	Apolipoprotein J (clusterin) and Alzheimer's disease. Microscopy Research and Technique, 2000, 50, 305-315.	2.2	226
5	Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid Î² peptides. Biochemical Journal, 2000, 348, 359-365.	3.7	219
6	Systemic Catabolism of Alzheimer's AÎ²40 and AÎ²42. Journal of Biological Chemistry, 2004, 279, 45897-45908.	3.4	156
7	Regional Distribution of Amyloid-Bri Deposition and Its Association with Neurofibrillary Degeneration in Familial British Dementia. American Journal of Pathology, 2001, 158, 515-526.	3.8	127
8	Familial Danish Dementia: A Novel Form of Cerebral Amyloidosis Associated with Deposition of Both Amyloid-Dan and Amyloid-Beta. Journal of Neuropathology and Experimental Neurology, 2002, 61, 254-267.	1.7	116
9	Sequential Amyloid-Î² Degradation by the Matrix Metalloproteases MMP-2 and MMP-9. Journal of Biological Chemistry, 2015, 290, 15078-15091.	3.4	107
10	Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloidâ€Î² variants in cells composing the cerebral vessel walls. FASEB Journal, 2010, 24, 229-241.	0.5	74
11	Systemic Amyloid Deposits in Familial British Dementia. Journal of Biological Chemistry, 2001, 276, 43909-43914.	3.4	73
12	The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiology of Disease, 2016, 86, 29-40.	4.4	73
13	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	7.9	63
14	Complement Activation in Chromosome 13 Dementias. Journal of Biological Chemistry, 2002, 277, 49782-49790.	3.4	59
15	Familial Danish Dementia. Journal of Biological Chemistry, 2005, 280, 36883-36894.	3.4	59
16	AÎ² truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 208-225.	3.8	53
17	Iowa Variant of Familial Alzheimerâ€™s Disease. American Journal of Pathology, 2010, 176, 1841-1854.	3.8	49
18	Amyloidosis Associated with Cerebral Amyloid Angiopathy: Cell Signaling Pathways Elicited in Cerebral Endothelial Cells. Journal of Alzheimer's Disease, 2014, 42, S167-S176.	2.6	49

#	Article	IF	Citations
19	Matrix Metalloproteinase 2 (MMP-2) Degrades Soluble Vasculotropic Amyloid-Î² E22Q and L34V Mutants, Delaying Their Toxicity for Human Brain Microvascular Endothelial Cells. Journal of Biological Chemistry, 2010, 285, 27144-27158.	3.4	43
20	Nrf2 activation through the PI3K/GSK-3 axis protects neuronal cells from AÎ²-mediated oxidative and metabolic damage. Alzheimer's Research and Therapy, 2020, 12, 13.	6.2	42
21	Insights into Caspase-Mediated Apoptotic Pathways Induced by Amyloid-Î² in Cerebral Microvascular Endothelial Cells. Neurodegenerative Diseases, 2012, 10, 324-328.	1.4	41
22	Dutch and arctic mutant peptides of Î² amyloid1â€“40 differentially affect the FGF-2 pathway in brain endothelium. Experimental Cell Research, 2009, 315, 385-395.	2.6	39
23	Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid Î² and the Asn23 Iowa mutation. Biochemical Journal, 2013, 456, 347-360.	3.7	39
24	Alzheimerâ€™s amyloid Î² heterogeneous species differentially affect brain endothelial cell viability, bloodâ€brain barrier integrity, and angiogenesis. Aging Cell, 2020, 19, e13258.	6.7	39
25	Isolation and Biochemical Characterization of Amyloid Plaques and Paired Helical Filaments. Current Protocols in Cell Biology, 2009, 44, Unit 3.33 3.33.1-33.	2.3	38
26	Tumoral non-amyloidotic monoclonal immunoglobulin light chain deposits (â€˜aggregomaâ€™): presenting feature of B-cell dyscrasia in three cases with immunohistochemical and biochemical analyses. British Journal of Haematology, 2002, 119, 62-69.	2.5	34
27	In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's AÎ² protein. Frontiers in Aging Neuroscience, 2016, 8, 223.	3.4	34
28	pH-dependent fibrillogenesis of a VÎºIII Bence Jones protein. British Journal of Haematology, 1999, 107, 835-843.	2.5	31
29	Chromosome 13 dementia syndromes as models of neurodegeneration. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 277-284.	3.0	29
30	Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: Similarities with Alzheimer's disease. Journal of the Neurological Sciences, 2007, 257, 88-96.	0.6	24
31	Oxidative stress and mitochondria-mediated cell death mechanisms triggered by the familial Danish dementia ADan amyloid. Neurobiology of Disease, 2016, 85, 130-143.	4.4	21
32	CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE. Hirosaki Medical Journal, 2010, 61, S111-S124.	1.0	16
33	Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2457-2467.	3.8	14
34	Preamyloid Lesions and Cerebrovascular Deposits in the Mechanism of Dementia: Lessons from Non-Î²-Amyloid Cerebral Amyloidosis. Neurodegenerative Diseases, 2008, 5, 173-175.	1.4	11
35	Oxidative Stress, Chronic Inflammation, and Amyloidoses. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-2.	4.0	9
36	Ion channel formation by N-terminally truncated AÎ² (4â€“42): relevance for the pathogenesis of Alzheimer's disease. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102235.	3.3	9

#	Article	IF	Citations
37	Unveiling Brain AÎ² Heterogeneity Through Targeted Proteomic Analysis. Methods in Molecular Biology, 2018, 1779, 23-43.	0.9	8
38	N-terminally truncated AÎ²4-x proteoforms and their relevance for Alzheimerâ€™s pathophysiology. Translational Neurodegeneration, 2022, 11, .	8.0	7
39	Alzheimerâ€like pathology in trisomy 21 cerebral organoids amenable to pharmacological inhibition reveals BACE2 as a geneâ€doseâ€sensitive ADâ€suppressor in human brain. Alzheimer's and Dementia, 2020, 16, e043136.	0.8	6
40	Proteomic Analysis Shows Constitutive Secretion of MIF and p53-associated Activity of COX-2 â^'/â^' Lung Fibroblasts. Genomics, Proteomics and Bioinformatics, 2017, 15, 339-351.	6.9	5
41	Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan. Neurobiology of Disease, 2021, 158, 105452.	4.4	5
42	Apolipoprotein J (clusterin) and Alzheimer's disease. Microscopy Research and Technique, 2000, 50, 305-315.	2.2	5
43	O2-12-01: MITOCHONDRIA AND DEATH RECEPTORS: KEY TARGETS FOR AMYLOID TOXICITY IN THE CEREBRAL VASCULATURE. , 2014, 10, P191-P191.		0
44	P1-109: MITOCHONDRIAL DYSFUNCTION INDUCED BY A POSTTRANSLATIONALLY MODIFIED AMYLOID LINKED TO A FAMILIAL MUTATION IN AN ALTERNATIVE MODEL OF NEURODEGENERATION. , 2014, 10, P341-P341.		0
45	P4-209: Methazolamide protects neuronal and glial cells from amyloid toxicity in vitro and in vivo via mitochondria-mediated mechanisms. , 2015, 11, P860-P861.		0
46	Amyloid beta oligomers trigger death receptorsâ€mediated apoptosis in cerebral endothelial cells. FASEB Journal, 2012, 26, 752.8.	0.5	0
47	Enhanced Brain Retention of AÎ²4â€x Proteoforms and its Contribution to Amyloid Deposits in Alzheimerâ€™s Disease. FASEB Journal, 2022, 36, .	0.5	0
48	The Extracellular Chaperone Clusterin in AÎ² and Nonâ€AÎ² Cerebral Amyloidoses. FASEB Journal, 2022, 36, .	0.5	0
49	Identification of Clusterin as a Major ABri- and ADan-Binding Protein Using Affinity Chromatography. Methods in Molecular Biology, 2022, 2466, 49-60.	0.9	0